Amedco - Quiz
January JPGN Articles
Proxy?reported outcome measures (i.e., reports by someone who is not the patient responding as if that person were the patient) are discouraged for use in registration trials as suggested by the FDA PRO Guidance. Which of the following measurement tools uses proxy?reported outcome measures?
A - Mayo score
B - Pediatric Ulcerative Colitis Activity Index (PUCAI)
C - Modified Ulcerative Colitis Activity Index (MUCAI)
D - All of the above
Only three drugs have been approved by the FDA for the treatment of pediatric ulcerative colitis (UC). Which of the following choices contains all these 3 approved drugs?
A - Azulfidine, Colazal, and Remicade
B - Pentasa, Imuran, Azanin
C - Imuran, Azanin, Apriso
Which of the following disease activity indices used in the pediatric UC trials is a FDA preferred measurement for the pediatric UC trials?
A - Pediatric UC Activity Index (PUCAI)
B - Simple Clinical Colitis Activity Index (SCCAI)
C - Sutherland UC Activity Index
D - None of above
CF patients are potential candidates for probiotic supplementation because:
A - Probiotics can help treat atopic disease.
B - Probiotics directly improve their respiratory function.
C - The intestinal microflora of CF patients is often abnormal, due to repeated antibiotic use.
What are the mechanisms supporting the use of L.reuteri strains in this study?
A - The anti-inflammatory intestinal activity of different LR strains has been documented through inhibition of colitis in transgenic IL-10 deficient mice.
B - Some LR strains exhibit a potent inhibitory effect on TNF-a induced IL-8 expression in human intestinal epithelial cells.
C - All of the answers above.
Which of the following were noted in this study using L.Reuteri ATCC55730 in cystic fibrosis?
A - Reducing rate of pulmonary exacerbations and upper respiratory infections.
B - Improvement of the FEV1.
C - significant changes in TNF-alpha and IL-8 plasmatic concentration.
D - Decreasing number of gastrointestinal infections.
Copyright © 2015
- 90 W Country Road C Suite 300 St. Paul, Minnesota 55117 |